Saturday, April 12, 2008

New Wesley Research Institute Study Aims To Halt The Progression Of Multiple Sclerosis

Adult stem cell therapy generating excitement for treatment of disease
WSBT-TV - South Bend,IN,USA
A review of hundreds of trials found in some patients adult stem cells have stopped auto-immune diseases like rheumatoid arthritis and multiple sclerosis. ...
See all stories on this topic

Acorda Therapeutics Signs GGF2 Manufacturing Agreement with CMC ICOS
PR-Inside.com (Pressemitteilung) - Wien,Austria
Acorda's lead clinical product, Fampridine-SR, is in Phase 3 clinical trials to evaluate its safety and efficacy to improve walking ability in people with ...
See all stories on this topic

MediciNova reports encouraging results from Phase II multiple ...
Pharmaceutical Business Review - USA
Brain volume loss was significantly less (p=0.030) in patients receiving 60mg per day of MN-166 for 24 months compared to the other treatment groups. ...
See all stories on this topic


New Wesley Research Institute Study Aims To Halt The Progression Of Multiple Sclerosis
A new research study being conducted at The Wesley Research Institute (WRI) aims to stop the progression of early active stage Multiple Sclerosis (MS) in its tracks.There are currently more than 2.
Genetic Factor In Brain Development Revealed
In the earliest days of brain development, the brain's first cells - neuroepithelial stem cells - divide continuously, producing a population of cells that eventually evolves into the various cells of the fully formed brain.

Increasing Positive Experiences Decreases Depression Symptoms In Patients With Multiple Sclerosis
Depression is prevalent among people living with chronic diseases, such as multiple sclerosis (MS). Although most people with MS live normal lives, they must manage symptoms and treatments that cause increased emotional and psychological stress on a daily basis.


Norwegian Researchers Confirm Higher Rates Of Symptoms Of Depression And Anxiety In People With MS
Researchers in Norway found symptoms of depression and anxiety to be significantly higher among people with MS compared with those without MS. This study provides important data on the occurrence of emotional changes in people with MS, and the necessity to increase treatment of these symptoms.


Drug costs could land mom with MS in care
London Free Press - Canada
By JOHN MINER, SUN MEDIA EXETER -- Denise Halpenny's biggest fear is losing use of her left hand when she quits taking the drug for multiple sclerosis that ...
See all stories on this topic


Improving Understanding Of The Brain, Learning And Memory
Neurons spoke to Dr. Joe Z. Tsien when he was a sophomore college student searching for some meaningful extracurricular activity.He had stopped by the lab of a brain researcher at Shanghai's East China Normal University.

Icahn files suit to gain access to Biogen records
Reuters - USA
The Cambridge, Massachusetts-based company, one of the world's biggest biotechnology companies and maker of multiple sclerosis drugs Avonex and Tysabri, ...
See all stories on this topic


In Lou Gehrig's Disease Leaky Blood Vessels Open Up Nerve Cells To Toxic Assault
Leaky blood vessels that lose their ability to protect the spinal cord from toxins may play a role in the development of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, according to research published in the April issue of Nature Neuroscience.

Study shows caffeine prevents Multiple Sclerosis-like disease
News 10 Now Syracuse Fri, 11 Apr 2008 5:35 PM PDT
Six to eight cups of coffee a day is shown to prevent mice from developing a disease similar to multiple sclerosis. This according to a new Cornell University study. But don't start downing lots of lattes. The Cornell researchers involved say it's actually the caffeine that's key. Our Allison Lazarz breaks down this new study and how it could affect millions of people.



Status Of The E2007 (perampanel) Development Program
Medical News Today Sat, 12 Apr 2008 1:15 AM PDT
E2007 (perampanel) is a first-in-class, orally administered, highly selective non-competitive AMPA-type glutamate receptor antagonist, in development by Eisai for several indications, including Parkinson's disease, neuropathic pain, epilepsy, multiple sclerosis and migraine prophylaxis. The AMPA receptor is widely present in almost all excitatory neuronal synapses.

New Wesley Research Institute Study Aims To Halt The Progression Of Multiple Sclerosis

Main Category: Multiple Sclerosis

Also Included In: Immune System / Vaccines

Article Date: 09 Apr 2008 - 2:00 PDT
A new research study being conducted at The Wesley Research Institute (WRI) aims to stop the progression of early active stage Multiple Sclerosis (MS) in its tracks.
There are currently more than 2.5 million people worldwide with MS, a chronic disease that affects the central nervous system.
They suffer from a range of debilitating symptoms including impaired gait and mobility, bladder and bowel dysfunction, cognitive and visual impairment, and profound muscle weakness.
Principal Investigator of the project at the WRI, Dr Pamela McCombe, is a neurologist at both The Wesley Hospital and Royal Brisbane and Women's Hospital, and also Chairman of the WRI Research Committee.
"This study might prove to be the strongest, most effective treatment of MS ever."
"Current treatments for MS only reduce the progression rate of the disease. This new treatment, if successful, will actually halt the progression of MS."
"Not only does it aim to stop MS in its tracks but it will also spare MS sufferers from weekly injections replacing them with infusions over three consecutive days every year."
"The medication targets lymphocytes (a type of white blood cell) to decrease the inflammatory reaction responsible for the progression of MS."
Preliminary studies have demonstrated that as a result of this medication sufferers have experienced fewer disease relapses, a decrease in the formation of central nervous system lesions and a reduction in cumulative disabilities.
"This suggests to me that there is every chance this medication will prove successful and become widely used."
This is an international study involving 200 sites. The WRI is one of fifteen sites in Australia to trial this new treatment, and one of only two in Queensland. The other site is the Gold Coast Hospital.
The Multiple Sclerosis Society of Queensland said in a statement: "The Multiple Sclerosis Society of Queensland welcomes the participation of local researchers in ground breaking research that may one day provide freedom from MS for the thousands of Australians living with this disease, and endorses the quality of the contribution of Queensland research in this exciting world-wide effort."
----------------------------
Article adapted by Medical News Today from original press release.
----------------------------
This MS study forms part of the WRI's commitment to furthering neurological research, which also includes research into better treatment and diagnoses of brain tumours and stroke.
The WRI is currently recruiting volunteers for this study. For more information visit http://www.wesleyresearch.org.au/. The research study is ethically approved and there are no costs associated with participation.
The Wesley Research Institute is an independent, not-for-profit medical research institute based in Brisbane that conducts research that that aims for immediate improvements to quality of life through better diagnosis, treatment and rehabilitation.
Source: Colleen McMillan
Research Australia
http://www.medicalnewstoday.com/articles/103241.php

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home